{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:39:38Z","timestamp":1785465578019,"version":"3.56.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02606-6","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:25:48Z","timestamp":1747815948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging risks of lipid-lowering therapy and low LDL levels: implications for eye, brain, and new-onset diabetes"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-135X","authenticated-orcid":false,"given":"Erkan","family":"Cure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-6459","authenticated-orcid":false,"given":"Medine","family":"Cumhur Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: A compass for future health. J Am Coll Cardiol. 2022;80:2361\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.005.","journal-title":"J Am Coll Cardiol"},{"key":"2606_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The heart of the world. Glob Heart. 2024;19:11. https:\/\/doi.org\/10.5334\/gh.1288.","journal-title":"Glob Heart"},{"key":"2606_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18:689\u2013700. https:\/\/doi.org\/10.1038\/s41569-021-00541-4.","journal-title":"Nat Rev Cardiol"},{"key":"2606_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, Palagashvilli T, et al. GOULD investigators. Use of Lipid-Lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1060\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"key":"2606_CR5","doi-asserted-by":"publisher","first-page":"e023690","DOI":"10.1161\/JAHA.121.023690","volume":"11","author":"S Rong","year":"2022","unstructured":"Rong S, Li B, Chen L, Sun Y, Du Y, Liu B, et al. Association of Low-Density lipoprotein cholesterol levels with more than 20-Year risk of cardiovascular and All-Cause mortality in the general population. J Am Heart Assoc. 2022;11:e023690. https:\/\/doi.org\/10.1161\/JAHA.121.023690.","journal-title":"J Am Heart Assoc"},{"key":"2606_CR6","unstructured":"https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/lipidology-update-targets-and-timing-of-well-established-therapies"},{"key":"2606_CR7","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.3390\/jcm12237432","volume":"12","author":"JE Jones","year":"2023","unstructured":"Jones JE, Tang KS, Barseghian A, Wong ND. Evolution of more aggressive LDL-Cholesterol targets and therapies for cardiovascular disease prevention. J Clin Med. 2023;12:7432. https:\/\/doi.org\/10.3390\/jcm12237432.","journal-title":"J Clin Med"},{"key":"2606_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","volume":"396","author":"B Gencer","year":"2020","unstructured":"Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of Lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(20)32332-1.","journal-title":"Lancet"},{"key":"2606_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and safety of Statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(18)31942-1.","journal-title":"Lancet"},{"key":"2606_CR10","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","volume":"18","author":"O Mhaimeed","year":"2024","unstructured":"Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better. Am J Prev Cardiol. 2024;18:100649. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100649.","journal-title":"Am J Prev Cardiol"},{"key":"2606_CR11","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. FOURIER investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor Evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)32290-0.","journal-title":"Lancet"},{"key":"2606_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328\u201350. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312782.","journal-title":"Circ Res"},{"key":"2606_CR13","doi-asserted-by":"publisher","unstructured":"Zeng W, Deng H, Luo Y, Zhong S, Huang M, Tomlinson B. Advances in Statin adverse reactions and the potential mechanisms: A systematic review. J Adv Res. 2024:S2090-1232(24)00598-8. https:\/\/doi.org\/10.1016\/j.jare.2024.12.020","DOI":"10.1016\/j.jare.2024.12.020"},{"key":"2606_CR14","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1161\/CIRCRESAHA.119.315210","volume":"124","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Curtis AJ, Breslin M, Nelson M, Regarding Article. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124:e120. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315210.","journal-title":"Circ Res"},{"key":"2606_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1161\/CIRCULATIONAHA.118.036846","volume":"138","author":"R Peto","year":"2018","unstructured":"Peto R, Collins R. Trust the blinded randomized evidence that Statin therapy rarely causes symptomatic side effects. Circulation. 2018;138:1499\u2013501. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036846.","journal-title":"Circulation"},{"key":"2606_CR16","doi-asserted-by":"publisher","unstructured":"Sung KC, Huh JH, Ryu S, Lee JY, Scorletti E, Byrne CD, et al. Low levels of low-density lipoprotein cholesterol and mortality outcomes in non\u2010statin users. J Clin Med. 2019;8. https:\/\/doi.org\/10.3390\/jcm8101571.","DOI":"10.3390\/jcm8101571"},{"key":"2606_CR17","doi-asserted-by":"publisher","unstructured":"Zaman S, Wasfy JH, Kapil V, Ziaeian B, Parsonage WA, Sriswasdi S et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025:S0140-6736(25)00055\u2013\u20098. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315210https:\/\/doi.org\/10.1016\/PIIS0140-6736(25)00055-8","DOI":"10.1161\/CIRCRESAHA.119.315210"},{"key":"2606_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-326062","author":"Y Ma","year":"2025","unstructured":"Ma Y, Wu Y, Hu L, Chen W, Zhang X, Zheng D, et al. Associations between serum lipids and glaucoma: a cohort study of 400 229 UK biobank participants. Br J Ophthalmol. 2025. https:\/\/doi.org\/10.1136\/bjo-2024-326062. bjo-2024-326062.","journal-title":"Br J Ophthalmol"},{"key":"2606_CR19","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1212\/WNL.0000000000007853","volume":"93","author":"C Ma","year":"2019","unstructured":"Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, Neumann S, et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study. Neurology. 2019;93:e445\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000007853.","journal-title":"Neurology"},{"key":"2606_CR20","doi-asserted-by":"publisher","first-page":"1239335","DOI":"10.3389\/fendo.2023.1239335","volume":"14","author":"M Laakso","year":"2023","unstructured":"Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023;14:1239335. https:\/\/doi.org\/10.3389\/fendo.2023.1239335.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2606_CR21","first-page":"333","volume":"45","author":"E Tedeschi-Reiner","year":"2004","unstructured":"Tedeschi-Reiner E, Reiner Z, Sonicki Z. Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins. Croat Med J. 2004;45:333\u20137.","journal-title":"Croat Med J"},{"key":"2606_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.amjcard.2005.05.070","volume":"96","author":"E Tedeschi-Reiner","year":"2005","unstructured":"Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. Am J Cardiol. 2005;96:1107\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2005.05.070.","journal-title":"Am J Cardiol"},{"key":"2606_CR23","doi-asserted-by":"publisher","first-page":"e000032","DOI":"10.1136\/bmjophth-2016-000032","volume":"1","author":"KKW Chan","year":"2017","unstructured":"Chan KKW, Tang F, Tham CCY, Young AL, Cheung CY. Retinal vasculature in glaucoma: a review. BMJ Open Ophthalmol. 2017;1:e000032. https:\/\/doi.org\/10.1136\/bmjophth-2016-000032.","journal-title":"BMJ Open Ophthalmol"},{"key":"2606_CR24","doi-asserted-by":"publisher","first-page":"110320","DOI":"10.1016\/j.exer.2025.110320","volume":"254","author":"WK Subczynski","year":"2025","unstructured":"Subczynski WK, Collery RF, Widomska J. Why has evolution selected for the human eye lens to use an extremely high cholesterol content as a protective mechanism against opacification? Exp Eye Res. 2025;254:110320. https:\/\/doi.org\/10.1016\/j.exer.2025.110320.","journal-title":"Exp Eye Res"},{"key":"2606_CR25","first-page":"1306","volume":"12","author":"N Tserentsoodol","year":"2006","unstructured":"Tserentsoodol N, Sztein J, Campos M, Gordiyenko NV, Fariss RN, Lee JW, et al. Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. Mol Vis. 2006;12:1306\u201318.","journal-title":"Mol Vis"},{"key":"2606_CR26","doi-asserted-by":"publisher","first-page":"e0264787","DOI":"10.1371\/journal.pone.0264787","volume":"17","author":"E L\u00e9ger-Charnay","year":"2022","unstructured":"L\u00e9ger-Charnay E, Gambert S, Martine L, Dubus E, Maire MA, Buteau B, et al. Retinal cholesterol metabolism is perturbated in response to experimental glaucoma in the rat. PLoS ONE. 2022;17:e0264787. https:\/\/doi.org\/10.1371\/journal.pone.0264787.","journal-title":"PLoS ONE"},{"key":"2606_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/nu8100663","volume":"8","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang M, Zhang X, Zhang Q, Nie J, Zhang M, et al. The association between the lipids levels in blood and risk of Age-Related macular degeneration. Nutrients. 2016;8:663. https:\/\/doi.org\/10.3390\/nu8100663.","journal-title":"Nutrients"},{"key":"2606_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","volume":"173","author":"N Ferri","year":"2016","unstructured":"Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2016;173:19\u201329. https:\/\/doi.org\/10.1016\/j.trsl.2015.10.004.","journal-title":"Transl Res"},{"key":"2606_CR29","first-page":"1319","volume":"12","author":"N Tserentsoodol","year":"2006","unstructured":"Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodriguez IR. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis. 2006;12:1319\u201333.","journal-title":"Mol Vis"},{"key":"2606_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.04.003","volume":"54","author":"NG Lambert","year":"2016","unstructured":"Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Wride MA, Padilla M, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. 2016;54:64\u2013102. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.003.","journal-title":"Prog Retin Eye Res"},{"key":"2606_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2022.4808","volume":"8","author":"CA Curcio","year":"2023","unstructured":"Curcio CA, Johnson M. Cholesteryl ester transfer protein inhibitors and access to the retina in Age-Related macular degeneration. JAMA Cardiol. 2023;8:206. https:\/\/doi.org\/10.1001\/jamacardio.2022.4808.","journal-title":"JAMA Cardiol"},{"key":"2606_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2022.4805","volume":"8","author":"LT Nordestgaard","year":"2023","unstructured":"Nordestgaard LT, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Cholesteryl ester transfer protein inhibitors and access to the retina in Age-Related macular Degeneration-Reply. JAMA Cardiol. 2023;8:206\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2022.4805.","journal-title":"JAMA Cardiol"},{"key":"2606_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/aos.14769","volume":"100","author":"L Posch-Pertl","year":"2022","unstructured":"Posch-Pertl L, Michelitsch M, Wagner G, Wildner B, Silbernagel G, Pregartner G, et al. Cholesterol and glaucoma: a systematic review and meta-analysis. Acta Ophthalmol. 2022;100:148\u201358. https:\/\/doi.org\/10.1111\/aos.14769.","journal-title":"Acta Ophthalmol"},{"key":"2606_CR34","doi-asserted-by":"publisher","first-page":"1122994","DOI":"10.1155\/2022\/1122994","volume":"2022","author":"G Huang","year":"2022","unstructured":"Huang G, Wang J, Li L, Gao Y, Yan Y. Meta-Analysis of dyslipidemia and blood lipid parameters on the risk of primary Open-Angle Glaucoma. Comput Math Methods Med. 2022;2022:1122994. https:\/\/doi.org\/10.1155\/2022\/1122994.","journal-title":"Comput Math Methods Med"},{"key":"2606_CR35","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41598-025-85505-1","volume":"15","author":"KI Jung","year":"2025","unstructured":"Jung KI, Kim YC, Shin HJ, Park CK. Nationwide cohort study of primary open angle glaucoma risk and cardiovascular factors among in Korean glaucoma suspects. Sci Rep. 2025;15:1952. https:\/\/doi.org\/10.1038\/s41598-025-85505-1.","journal-title":"Sci Rep"},{"key":"2606_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ophtha.2022.04.023","volume":"129","author":"KM Madjedi","year":"2022","unstructured":"Madjedi KM, Stuart KV, Chua SYL, Luben RN, Warwick A, Pasquale LR, et al. Modifiable risk factors for Glaucoma collaboration and the UK biobank eye and vision consortium. The association between serum lipids and intraocular pressure in 2 large united Kingdom cohorts. Ophthalmology. 2022;129:986\u201396. https:\/\/doi.org\/10.1016\/j.ophtha.2022.04.023.","journal-title":"Ophthalmology"},{"key":"2606_CR37","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44:1394\u2013407. https:\/\/doi.org\/10.1093\/eurheartj\/ehac605.","journal-title":"Eur Heart J"},{"key":"2606_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.04.003","author":"AM Elhusseiny","year":"2025","unstructured":"Elhusseiny AM, Eleiwa TK, Dihan QA, Chauhan MZ, Al\u2019Aref SJ, Lee RK. Racial and ethnic differences in the association between Statin use and the risk of ocular hypertension and Open-Angle Glaucoma. Am J Ophthalmol. 2025. https:\/\/doi.org\/10.1016\/j.ajo.2025.04.003. Epub ahead of print. S0002-9394(25)00170-9.","journal-title":"Am J Ophthalmol"},{"key":"2606_CR39","doi-asserted-by":"publisher","first-page":"e2018","DOI":"10.1097\/MD.0000000000002018","volume":"94","author":"HY Chen","year":"2015","unstructured":"Chen HY, Hsu SY, Chang YC, Lin CC, Sung FC, Chen WC, et al. Association between Statin use and Open-angle Glaucoma in hyperlipidemia patients: A Taiwanese Population-based Case-control study. Med (Baltim). 2015;94:e2018. https:\/\/doi.org\/10.1097\/MD.0000000000002018.","journal-title":"Med (Baltim)"},{"key":"2606_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/bjophthalmol-2021-318789","volume":"107","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wang W, Shang X, Xiong R, Ha J, Zhang L, et al. Association between Statin use and the risks of glaucoma in Australia: a 10-year cohort study. Br J Ophthalmol. 2023;107:66\u201371. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-318789.","journal-title":"Br J Ophthalmol"},{"key":"2606_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00417-024-06620-9","volume":"263","author":"SY Pan","year":"2025","unstructured":"Pan SY, Chen YY, Hsu MY, Sheen YJ, Weng CH, Lu YA, et al. Associations of different types of Statins with the risk of open-angle glaucoma: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2025;263:201\u20138. https:\/\/doi.org\/10.1007\/s00417-024-06620-9.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2606_CR42","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ogla.2024.07.008","volume":"7","author":"SY Lee","year":"2024","unstructured":"Lee SY, Paul ME, Coleman AL, Kitayama K, Yu F, Pan D, et al. Associations between Statin use and Glaucoma in the all of Us research program. Ophthalmol Glaucoma. 2024;7:563\u201371. https:\/\/doi.org\/10.1016\/j.ogla.2024.07.008.","journal-title":"Ophthalmol Glaucoma"},{"key":"2606_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000453040","volume":"26","author":"Z Xiao","year":"2017","unstructured":"Xiao Z, Gong X. Use of Statins and risk of reducing glaucoma: is there a link?? Med Princ Pract. 2017;26:296. https:\/\/doi.org\/10.1159\/000453040.","journal-title":"Med Princ Pract"},{"key":"2606_CR44","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of Statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"2606_CR45","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41598-023-29613-w","volume":"13","author":"JA Choi","year":"2023","unstructured":"Choi JA, Lee SN, Jung SH, Won HH, Yun JS. Association of glaucoma and lifestyle with incident cardiovascular disease: a longitudinal prospective study from UK biobank. Sci Rep. 2023;13:2712. https:\/\/doi.org\/10.1038\/s41598-023-29613-w.","journal-title":"Sci Rep"},{"key":"2606_CR46","doi-asserted-by":"publisher","first-page":"bvz038","DOI":"10.1210\/jendso\/bvz038","volume":"4","author":"DD Bikle","year":"2020","unstructured":"Bikle DD, Vitamin D. Newer concepts of its metabolism and function at the basic and clinical level. J Endocr Soc. 2020;4:bvz038. https:\/\/doi.org\/10.1210\/jendso\/bvz038.","journal-title":"J Endocr Soc"},{"issue":"23","key":"2606_CR47","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1016\/j.febslet.2006.07.027","volume":"580","author":"HR Waterham","year":"2006","unstructured":"Waterham HR. Defects of cholesterol biosynthesis. FEBS Lett. 2006;580(23):5442\u20139. https:\/\/doi.org\/10.1016\/j.febslet.2006.07.027.","journal-title":"FEBS Lett"},{"key":"2606_CR48","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1038\/s41467-023-43892-x","volume":"14","author":"M P\u00f6hnl","year":"2023","unstructured":"P\u00f6hnl M, Trollmann MFW, B\u00f6ckmann RA. Nonuniversal impact of cholesterol on membranes mobility, curvature sensing and elasticity. Nat Commun. 2023;14:8038. https:\/\/doi.org\/10.1038\/s41467-023-43892-x.","journal-title":"Nat Commun"},{"key":"2606_CR49","doi-asserted-by":"publisher","unstructured":"Kim Y, Parolek J, Burd CG. Cholesterol depletion activates [preprint]rafficking-coupled sphingolipid synthesis. BioRxiv [Preprint]. 2025:2025.02.12.637879 https:\/\/doi.org\/10.1101\/2025.02.12.637879.","DOI":"10.1101\/2025.02.12.637879"},{"key":"2606_CR50","unstructured":"Hypolipidemia. Merck Manual Professional Version. https:\/\/www.merckmanuals.com\/professional\/endocrine-and-metabolic-disorders\/lipid-disorders\/hypolipidemia Accessed May 23, 2024."},{"key":"2606_CR51","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/eurheartj\/ehaa1080","volume":"42","author":"AD Karagiannis","year":"2021","unstructured":"Karagiannis AD, Mehta A, Dhindsa DS, Virani SS, Orringer CE, Blumenthal RS, et al. How low is safe? The frontier of very low (<\u200930\u00a0mg\/dL) LDL cholesterol. Eur Heart J. 2021;42:2154\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1080.","journal-title":"Eur Heart J"},{"key":"2606_CR52","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","volume":"39","author":"PE Penson","year":"2018","unstructured":"Penson PE, Long DL, Howard G, Toth PP, Muntner P, Howard VJ, et al. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the reasons for geographical and Racial differences in stroke (REGARDS) study. Eur Heart J. 2018;39:3641\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehy533.","journal-title":"Eur Heart J"},{"key":"2606_CR53","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","volume":"46","author":"SD Wiviott","year":"2005","unstructured":"Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, Investigators PI-T. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive Statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2005.04.064.","journal-title":"J Am Coll Cardiol"},{"key":"2606_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2:547\u201355. https:\/\/doi.org\/10.1001\/jamacardio.2017.0083.","journal-title":"JAMA Cardiol"},{"key":"2606_CR55","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"2606_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose Atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549\u201359. https:\/\/doi.org\/10.1056\/NEJMoa061894.","journal-title":"N Engl J Med"},{"key":"2606_CR57","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, et al. American heart association Council on arteriosclerosis, thrombosis and vascular biology; Council on cardiovascular and stroke nursing; Council on peripheral vascular disease; and stroke Council. Aggressive LDL-C Lowering and the brain: impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2023;43:e404\u201342. https:\/\/doi.org\/10.1161\/ATV.0000000000000164.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2606_CR58","doi-asserted-by":"publisher","first-page":"e2286","DOI":"10.1212\/WNL.0000000000007454","volume":"92","author":"PM Rist","year":"2019","unstructured":"Rist PM, Buring JE, Ridker PM, Kase CS, Kurth T, Rexrode KM. Lipid levels and the risk of hemorrhagic stroke among women. Neurology. 2019;92:e2286\u201394. https:\/\/doi.org\/10.1212\/WNL.0000000000007454.","journal-title":"Neurology"},{"key":"2606_CR59","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awac186","volume":"145","author":"E Mayerhofer","year":"2022","unstructured":"Mayerhofer E, Malik R, Parodi L, Burgess S, Harloff A, Dichgans M, et al. Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk. Brain. 2022;145:2677\u201386. https:\/\/doi.org\/10.1093\/brain\/awac186.","journal-title":"Brain"},{"key":"2606_CR60","doi-asserted-by":"publisher","unstructured":"Shi S, Zheng Z, Chen W, Song Y, Dou K. Low density lipoprotein cholesterol but not Statins is the direct cause of intracerebral hemorrhage. Eur J Pharmacol. 2025;177443. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177443.","DOI":"10.1016\/j.ejphar.2025.177443"},{"key":"2606_CR61","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.1038\/s41598-025-91258-8","volume":"15","author":"S Zeng","year":"2025","unstructured":"Zeng S, Liu Q, Wu Y, Bai H, Fan P, Liu X. Reduced low-density lipoprotein cholesterol levels are associated with increased risk of gestational diabetes mellitus in Chinese women. Sci Rep. 2025;15:6435. https:\/\/doi.org\/10.1038\/s41598-025-91258-8.","journal-title":"Sci Rep"},{"key":"2606_CR62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4239\/wjd.v6.i2.234","volume":"6","author":"E Noctor","year":"2015","unstructured":"Noctor E, Dunne FP. Type 2 diabetes after gestational diabetes: the influence of changing diagnostic criteria. World J Diabetes. 2015;6:234\u201344. https:\/\/doi.org\/10.4239\/wjd.v6.i2.234.","journal-title":"World J Diabetes"},{"key":"2606_CR63","doi-asserted-by":"publisher","first-page":"e2148147","DOI":"10.1001\/jamanetworkopen.2021.48147","volume":"5","author":"RD Santos","year":"2022","unstructured":"Santos RD. Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular events in patients with severe Hypercholesterolemia-Moving forward with risk stratification and therapy. JAMA Netw Open. 2022;5:e2148147. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48147.","journal-title":"JAMA Netw Open"},{"key":"2606_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03533-w","author":"NA Marston","year":"2025","unstructured":"Marston NA, Kamanu FK, Melloni GEM, Schnitzler G, Hakim A, Ma RX, et al. Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid Lowering. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03533-w.","journal-title":"Nat Med"},{"key":"2606_CR65","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1016\/j.jacl.2024.08.003","volume":"18","author":"A Sayed","year":"2024","unstructured":"Sayed A, Swanson J, Kip K, Jesrani EK, Reis S, Saeed A. Long term association of low-density lipoprotein subtypes with coronary artery calcium score and atherosclerotic cardiovascular disease events: insights from the heartscore study. J Clin Lipidol. 2024;18:e938\u201345. https:\/\/doi.org\/10.1016\/j.jacl.2024.08.003.","journal-title":"J Clin Lipidol"},{"key":"2606_CR66","doi-asserted-by":"publisher","unstructured":"Malick WA, Choi D, Langsted A, Bittner V, Nordestgaard BG, Stroes ESG, et al. Challenges in achieving LDL cholesterol targets and novel approaches to lipid Lowering. Eur J Prev Cardiol. 2025;zwaf123. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf123. Epub ahead of print.","DOI":"10.1093\/eurjpc\/zwaf123"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02606-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:25:49Z","timestamp":1747815949000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02606-6","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}